Insight

Gustavo Viani summarising the RAPIDO trial

Photo of Gustavo Viani from onconews.com.br

Aug 20, 2024, 14:45

Gustavo Viani summarising the RAPIDO trial

Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, University of Sao Paulo, recently posted on X:

“ 2 CTH cycles less do not compromise the results with an increase CR-R:RAPIDO trial!

Methods:

high-risk locally advanced rectal cancer (LARC).
Study design: Prospective observational cohort study.
Treatment: Short-course leading to 4 CAPOX or 6 FOLFOX leading to mesorectal excision or watch-and-wait (W and W) for clinical complete response (cCR).
Complete response (CR), locoregional recurrences, neurotoxicity.

Outcomes:

CR rate: RAPIDO trial (24%).
LRR: decreased (around 5-6%).
Neurotoxicity: less than RAPIDO trial.”

Gustavo Viani

Source: Gustavo Viani/X

Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US).

Authors: Bengt Glimelius, Tanweer Khan, Karin Adolfsson, Eva Angenete, Åke Berglund, Kristina Bonde, Nils Elander, Tone Fokstuen, Johan Haux, Israa Imam, Cecilia Lagerbäck, Ingrid Ljuslinder, Andrzej Piwowar, Marie Zajicova, and Per J. Nilsson.

Gustavo Viani

Åke Berglund Andrzej Piwowar Bengt Glimelius cancer CAPOX Cecilia Lagerbäck clinical complete response Eva Angenete FOLFOX Gustavo Viani Ingrid Ljuslinder Israa Imam Johan Haux Karin Adolfsson Kristina Bonde LARC locally advanced rectal cancer Marie Zajicova Nils Elander OncoDaily Oncology Per J. Nilsson RAPIDO trial Tanweer Khan Tone Fokstuen

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage